In May, I attended the Alliance for Regenerative Medicine’s policy lunch, held in D.C. FDA Commissioner Scott Gottlieb, MD, was the keynote speaker and discussed the FDA’s policy on regenerative medicine. He outlined a new policy launch in respect to gene editing. He stated that the therapies have the potential to address hundreds, if not thousands, of different rare and common diseases.
There are 959 regenerative medicine clinical trials taking place worldwide. More than 53% of those are in oncology and nearly 10% in cardiovascular disorder. Regenerative medicine is playing an important role in finding cures and therapies and aims to alter the current practice of medicine by treating the root causes of disease. Regenerative medicine includes gene and cell therapies and tissue-engineered products which repair, replace and regenerate organs, cells and tissues in the body.
On October 11th, the Missouri Cures Education Foundation will co-host a Regenerative Medicine Symposium with Mid America Transplant. The purpose of the symposium is to raise awareness about regenerative medicine taking place in Missouri. Please watch for more details in the upcoming months.